Breakthrough Therapy Designation is designed to expedite the development and review of medicines intended to treat serious or life-threatening diseases, and to help ensure people have access to
The Series C round was led by Deerfield Management while RA Capital Management, Venrock, Foresite Capital, Perceptive Advisors and others made significant new investments in the gene therapy
SB26, also known as TAK-671, is a ulinastatin-Fc (UTI-Fc) fusion protein intended to treat severe acute pancreatitis. Non-clinical GLP safety studies performed in monkeys and rats supported early
Aralez has signed an agreement to sell its VIMOVO royalties and Canadian operations to Nuvo Pharmaceuticals for $110m. In another deal, the company agreed to offload its TOPROL-XL
The financing was led by Novo Holdings and joined by new investors Cowen Healthcare Investments, Pfizer Ventures and funds managed by Tekla Capital Management. Existing investors Versant Ventures,
Continuing its focus on enhancing shareholder value, the Board believes a separation of the Rx business will better enable this unique asset to capitalize on its platform of
The product is a novel therapeutic antibody, Clevegen, being developed by clinical stage biotechnology company, Faron Pharmaceuticals. The manufacture of this product took place at Abzena’s site in
Spark Therapeutics reported that although most of the patients could have their bleeding reduced by its gene therapy, one participant though did not quickly respond to oral steroids. The
The fast track designation gives BioCryst Pharmaceuticals the scope for frequent interactions with the FDA during development of the drug. It also gives the opportunity for priority review
Kapspargo Sprinkle, a U.S. Food and Drug Administration (FDA) approved, novel, patented formulation of metoprolol succinate, is the first and only extended-release sprinkle formulation of this beta1-selective adrenoreceptor
Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.